Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 660 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 660 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $25.46, for a total transaction of $16,803.60. Following the completion of the transaction, the chief financial officer now owns 120,960 shares of the company’s stock, valued at approximately $3,079,641.60. This trade represents a 0.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total transaction of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74.

BioLife Solutions Price Performance

Shares of BLFS opened at $25.83 on Friday. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The stock has a market cap of $1.21 billion, a PE ratio of -24.37 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm has a fifty day moving average price of $26.66 and a 200 day moving average price of $25.49.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the company earned ($0.21) earnings per share. As a group, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently made changes to their positions in the business. Harbor Capital Advisors Inc. boosted its stake in shares of BioLife Solutions by 31.0% during the third quarter. Harbor Capital Advisors Inc. now owns 52,449 shares of the medical equipment provider’s stock worth $1,313,000 after buying an additional 12,421 shares during the period. Principal Financial Group Inc. boosted its stake in shares of BioLife Solutions by 4.7% during the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after buying an additional 8,580 shares during the period. Summit Global Investments acquired a new stake in shares of BioLife Solutions during the third quarter worth about $228,000. Curi RMB Capital LLC boosted its stake in shares of BioLife Solutions by 0.5% during the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after buying an additional 2,283 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of BioLife Solutions during the third quarter worth about $57,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright boosted their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday. Northland Securities boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, Benchmark reiterated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.